Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088665 | 0.86 | HRH3 (0.64) | HRH3CYP2A6LOXL2RORC | |
| SCHEMBL15831721 | 0.86 | HRH3 (0.59) | HRH3CYP2A6LOXL2RORC | |
| SCHEMBL29278097 | 0.86 | LOXL2 (0.48) | HRH3CYP2A6LOXL2RORC | |
| SCHEMBL11804762 | 0.84 | CYP2A6 (0.58) | HRH3CYP2A6LOXL2HDAC8 | |
| SCHEMBL14376811 | 0.83 | CYP2A6 (0.46) | HRH3CYP2A6RORC | |
| SCHEMBL7768079 | 0.82 | HRH3 (0.84) | HRH3HDAC8HDAC6 | |
| SCHEMBL23374744 | 0.82 | CYP2A6 (0.57) | HRH3CYP2A6LOXL2 | |
| SCHEMBL2201240 | 0.80 | RORC (0.53) | HRH3CYP2A6RORC | |
| SCHEMBL6412394 | 0.79 | HRH3 (0.59) | HRH3HDAC8HDAC6 | |
| SCHEMBL6225284 | 0.79 | HRH3 (0.59) | HRH3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015767-A1 | PHOTOSENSITIVE COLORING COMPOSITION, CURED SUBSTANCE, COLOR FILTER, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND ASYMMETRIC DIKETOPYRROLOPYRROLE COMPOUND | FUJIFILM CORPORATION (JP) | 2023-01-19 | — | — | US | disclosed |
| US-9139557-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20130245003-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8436034-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-2121653-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298326-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-7799809-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2010-09-21 | — | — | US | disclosed |
| US-7728012-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-2121653-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008080969-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| EP-1551841-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298326-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885CYP2A6 247/4885LOXL2 4432/4885 |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885CYP2A6 247/4885LOXL2 4432/4885 |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885CYP2A6 247/4885LOXL2 4432/4885 |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | HRH3 768/4885CYP2A6 348/4885LOXL2 3527/4885 |
| US-20130245003-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885CYP2A6 247/4885LOXL2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.